JSPR
vs
S&P 500
JSPR
S&P 500
Over the past 12 months, JSPR has underperformed S&P 500, delivering a return of -72% compared to the S&P 500's +15% growth.
Stocks Performance
JSPR vs S&P 500
Performance Gap
JSPR vs S&P 500
Performance By Year
JSPR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Jasper Therapeutics Inc
Glance View
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 25 full-time employees. The company went IPO on 2019-11-20. The firm has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. The company is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The firm also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.